Literature DB >> 20589717

Overactive bladder: Is there a link to the metabolic syndrome in men?

Michael G Kirby1, Adrian Wagg, Linda Cardozo, Christopher Chapple, David Castro-Diaz, Dirk de Ridder, Montserrat Espuna-Pons, Francois Haab, Con Kelleher, Heinz Kölbl, Ian Milsom, Philip Van Kerrebroeck, Mark Vierhout, Stefano Salvatore, Andrea Tubaro.   

Abstract

It is becoming increasingly clear that a variety of metabolic, cardiovascular, and endocrine factors contribute to male pelvic health. In particular, a growing body of evidence suggests a relationship between lower urinary tract symptoms, benign prostatic hyperplasia, overactive bladder, erectile dysfunction, and the metabolic syndrome. This article explores these relationships, focusing on the role of the autonomic nervous system and hyperinsulinemia, together with their implications for urological practice.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20589717     DOI: 10.1002/nau.20892

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  22 in total

1.  Does metabolic syndrome increase the risk of infective complications after prostate biopsy? A critical evaluation.

Authors:  Cahit Sahin; Bilal Eryildirim; A Cihangir Cetinel; Gokhan Faydaci; Fehmi Narter; Cemal Goktas; Kemal Sarica
Journal:  Int Urol Nephrol       Date:  2015-01-15       Impact factor: 2.370

2.  Relationship of blood flow in the common iliac vein to lower urinary tract disease.

Authors:  Kimio Sugaya; Katsumi Kadekawa; Yoshihiro Unten; Saori Nishijima; Katsuhiro Ashitomi; Hideyuki Yamamoto
Journal:  J Med Ultrason (2001)       Date:  2019-02-08       Impact factor: 1.314

3.  Metabolic syndrome is predictive of lower urinary tract symptom improvement after holmium laser enucleation of the prostate for benign prostatic obstruction.

Authors:  Taekmin Kwon; Sejun Park; Sungchan Park; Kyung Hyun Moon
Journal:  Int Urol Nephrol       Date:  2017-03-30       Impact factor: 2.370

4.  The impact of abdominal aortic calcification and visceral fat obesity on lower urinary tract symptoms in patients with benign prostatic hyperplasia.

Authors:  Tadasu Motoya; Seiji Matsumoto; Satoshi Yamaguchi; Naoki Wada; Atsushi Numata; Hiroaki Osanai; Hidehiro Kakizaki
Journal:  Int Urol Nephrol       Date:  2014-06-08       Impact factor: 2.370

5.  Are blood vessels a target to treat lower urinary tract dysfunction?

Authors:  Martin C Michel; Russ Chess-Williams; Sharath S Hegde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-05-31       Impact factor: 3.000

6.  The Effect of Different Metabolic Syndrome: Definitions on the Relationship Between Metabolic Syndrome and LUTS in Men With Benign Prostatic Enlargement.

Authors:  Orhan Ünal Zorba; Hakkı Uzun; Görkem Akça; Selim Yazar
Journal:  Am J Mens Health       Date:  2016-06-23

7.  Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in a mouse model.

Authors:  Qiqi He; Melissa A Babcook; Sanjeev Shukla; Eswar Shankar; Zhiping Wang; Guiming Liu; Bernadette O Erokwu; Chris A Flask; Lan Lu; Firouz Daneshgari; Gregory T MacLennan; Sanjay Gupta
Journal:  Prostate       Date:  2016-04-04       Impact factor: 4.104

8.  Sensory dysfunction of bladder mucosa and bladder oversensitivity in a rat model of metabolic syndrome.

Authors:  Wei-Chia Lee; Po-Hui Chiang; You-Lin Tain; Chia-Ching Wu; Yao-Chi Chuang
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

9.  Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.

Authors:  Luiz O Leiria; Carolina Sollon; Marina C Calixto; Letícia Lintomen; Fabíola Z Mónica; Gabriel F Anhê; Gilberto De Nucci; Angelina Zanesco; Andrew D Grant; Edson Antunes
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  Risk of hospitalization for acute cardiovascular events among subjects with lower urinary tract symptoms: a nationwide population-based study.

Authors:  Huey-Juan Lin; Shih-Feng Weng; Chun-Ming Yang; Ming-Ping Wu
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.